These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 15798492)

  • 1. Psychotherapeutics and serotonin agonists and antagonists.
    Mertz H
    J Clin Gastroenterol; 2005; 39(5 Suppl 3):S247-50. PubMed ID: 15798492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.
    Gale JD
    Adv Ther; 2009 May; 26(5):519-30. PubMed ID: 19444393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Role of serotonin in the pathophysiology of the irritable bowel syndrome].
    Moskwa A; Boznańska P
    Wiad Lek; 2007; 60(7-8):371-6. PubMed ID: 18175558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic and therapeutic strategies in the irritable bowel syndrome.
    Cremonini F; Talley NJ
    Minerva Med; 2004 Oct; 95(5):427-41. PubMed ID: 15467518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of irritable bowel syndrome: novel approaches to the pharmacology of gut motility.
    Scarpignato C; Pelosini I
    Can J Gastroenterol; 1999 Mar; 13 Suppl A():50A-65A. PubMed ID: 10202210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripherally acting therapies for the treatment of irritable bowel syndrome.
    Saad RJ
    Gastroenterol Clin North Am; 2011 Mar; 40(1):163-82. PubMed ID: 21333906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.
    De Ponti F; Tonini M
    Drugs; 2001; 61(3):317-32. PubMed ID: 11293643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does co-administration of a non-selective opiate antagonist enhance acceleration of transit by a 5-HT4 agonist in constipation-predominant irritable bowel syndrome? A randomized controlled trial.
    Foxx-Orenstein AE; Camilleri M; Szarka LA; McKinzie S; Burton D; Thomforde G; Baxter K; Zinsmeister AR
    Neurogastroenterol Motil; 2007 Oct; 19(10):821-30. PubMed ID: 17539894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale for using serotonergic agents to treat irritable bowel syndrome.
    Baker DE
    Am J Health Syst Pharm; 2005 Apr; 62(7):700-11; quiz 712-3. PubMed ID: 15790796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability of tegaserod in irritable bowel syndrome management.
    Berardi RR
    J Am Pharm Assoc (2003); 2004; 44(1):41-51. PubMed ID: 14965152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug therapy options for patients with irritable bowel syndrome.
    Talley NJ
    Am J Manag Care; 2001 Jul; 7(8 Suppl):S261-7. PubMed ID: 11474911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irritable bowel syndrome: new pharmaceutical approaches to treatment.
    Farthing MJ
    Baillieres Best Pract Res Clin Gastroenterol; 1999 Oct; 13(3):461-71. PubMed ID: 10580922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies.
    Lewis JH
    Drug Saf; 2011 Jul; 34(7):545-65. PubMed ID: 21663331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of current drug therapies in irritable bowel syndrome: what works and does not work.
    Schoenfeld P
    Gastroenterol Clin North Am; 2005 Jun; 34(2):319-35, viii. PubMed ID: 15862938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tegaserod maleate in the treatment of irritable bowel syndrome: a clinical review.
    Rivkin A
    Clin Ther; 2003 Jul; 25(7):1952-74. PubMed ID: 12946544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alosetron in irritable bowel syndrome: strategies for its use in a common gastrointestinal disorder.
    Lembo A; Weber HC; Farraye FA
    Drugs; 2003; 63(18):1895-905. PubMed ID: 12930162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serotoninergic neuroenteric modulators.
    Talley NJ
    Lancet; 2001 Dec; 358(9298):2061-8. PubMed ID: 11755632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
    Rahimi R; Nikfar S; Abdollahi M
    Clin Ther; 2008 May; 30(5):884-901. PubMed ID: 18555935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The brain-gut axis in irritable bowel syndrome--clinical aspects.
    Mach T
    Med Sci Monit; 2004 Jun; 10(6):RA125-31. PubMed ID: 15173682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of tegaserod in the treatment of irritable bowel syndrome.
    Patel S; Berrada D; Lembo A
    Expert Opin Pharmacother; 2004 Nov; 5(11):2369-79. PubMed ID: 15500384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.